Who Manufactures Cerezyme?
Cerezyme is manufactured by Sanofi Genzyme, a business unit of the global healthcare company Sanofi [1].
What is Cerezyme used to treat?
Cerezyme is an enzyme replacement therapy used to treat Gaucher disease [2]. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a fatty substance called glucocerebroside. When this substance accumulates, it can cause enlarged organs, bone problems, and other serious health issues [3]. Cerezyme provides the deficient enzyme, beta-glucocerebrosidase, to help the body process glucocerebroside [2].
How does Cerezyme work?
Cerezyme contains imiglucerase, a recombinant form of the enzyme beta-glucocerebrosidase [2]. This enzyme is produced in a laboratory using genetic engineering. When administered intravenously, imiglucerase enters the bloodstream and helps to break down the accumulated glucocerebroside in cells throughout the body, thereby reducing the symptoms of Gaucher disease [4].
What are the potential side effects of Cerezyme?
Common side effects associated with Cerezyme treatment include itching, rash, hives, swelling, shortness of breath, nausea, vomiting, abdominal discomfort, headache, dizziness, and fatigue [5]. More serious side effects can include severe allergic reactions, including anaphylaxis, which requires immediate medical attention [5]. Patients may also develop antibodies to imiglucerase, although this does not always affect the drug's effectiveness [4].
How is Cerezyme administered?
Cerezyme is administered intravenously, meaning it is given directly into a vein, typically in a healthcare setting [4]. The frequency and duration of treatment depend on the severity of the Gaucher disease and the individual patient's response [2].
When was Cerezyme approved?
Cerezyme was approved by the U.S. Food and Drug Administration (FDA) in 1994 [6].
What are the alternatives to Cerezyme for Gaucher disease?
Other treatment options for Gaucher disease include other enzyme replacement therapies and substrate reduction therapies. VPRIV (velaglucerase alfa), manufactured by Shire (now Takeda), is another enzyme replacement therapy. Cerliponase alfa (used in Brineura) is approved for a different rare genetic disease, not Gaucher disease. Substrate reduction therapies, such as eliglustat (marketed as Cerdelga, also by Sanofi), work by reducing the production of glucocerebroside rather than replacing the missing enzyme [7].
Who is the parent company of Sanofi Genzyme?
Sanofi Genzyme is a business unit of Sanofi, a multinational pharmaceutical and healthcare company headquartered in Paris, France [1].
What is Gaucher disease?
Gaucher disease is an inherited metabolic disorder caused by a deficiency of the enzyme glucocerebrosidase [3]. This deficiency leads to the accumulation of fatty substances in organs like the spleen, liver, and bones, causing symptoms such as anemia, easy bruising, bone pain, and enlarged abdomen [3]. There are different types of Gaucher disease, with Type 1 being the most common and generally less severe [3].
What is the mechanism of action for enzyme replacement therapy?
Enzyme replacement therapy (ERT) involves administering a therapeutic enzyme to individuals who have a genetic defect causing them to produce insufficient amounts of a functional enzyme [4]. In the case of Gaucher disease, ERT provides a functional copy of the deficient enzyme, beta-glucocerebrosidase, which then helps to break down accumulated substrates in the body's cells, alleviating disease symptoms [4].
---
Sources:
[1] https://www.sanofi.com/
[2] https://www.sanofigenzyme.com/products/cerezyme
[3] https://medlineplus.gov/gaucherdisease.html
[4] https://www.ninds.nih.gov/health-information/disorders/gaucher-disease
[5] https://www.cerezyme.com/patients/how-to-take-cerezyme/side-effects
[6] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.getbatchnumber&DrugNameID=1009
[7] https://www.nhi.gov/healthcare-professionals/conditions/gaucher-disease/treatment-options